Giving cancer patients a second chance

The complexity of cancer demands a targeted approach to give patients their best shot at remission. We design cutting-edge immunotherapies to meet these needs.

LEARN MORE

Technology

Taking targeted
cancer treatment
to the next level.

BioSyngen is utilizing our proprietary EBV platform to develop next-generation CAR-T and TCR-T therapies to target EBV related cancers.

In activating a strong immune response, our therapies not only destroy cancer cells but also critically reduce off-target or on target off tumor toxicities to preserve healthy cells,—ensuring enhanced safety and clinical efﬁcacy in tandem.

Distinct approach to T-cell therapies.

Taking aim at
EBV antigens.

Epstein-Barr virus (EBV) related cancers are prevalent in Asia, yet most current therapies do not target such viral antigens. We are one of the few biotechs ﬁlling this gap in tumor immunotherapy.

Breaking barriers in
treating solid tumors.

Our therapies can effectively attack difﬁcult-to-treat solid tumors by better recognizing tumor specific antigens found on the cancer cells and overcoming immunosuppressive TME

Diverse patients,
adaptive solutions.

Our EBV TCR library is the largest in the world and covers Caucasian and Asian populations, giving us greater flexibility in designing personalized T cell therapies.

LEARN MORE

Pipeline

Translating treatments from bench to bedside.

Multiple clinical trials are underway to advance immunotherapy solutions, enabled by BioSyngen’s extensive clinical network and large-scale GMP manufacturing capabilities.

As we strive to create a brighter future for cancer patients and their families, Biosyngen is combining innovative technologieswith medical expertise en route to becoming a visionary biotechunicorn in Singapore and the region.

LEARN MORE

News

Latest Headlines

Feb 17, 2023

Biosyngen has obtained FDA IND clearance of BRG01 for Phase

February 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T ...

Oct 21, 2022

The IND application of Biosyngen BRG01 Therapy was accepted

GUANGZHOU, China, Sept. 28, 2022 /PRNewswire/ -- The IND application of Biosyngen BRG01 Therapy has been accepted for review by the Center for Drug Evaluation, China (CXSL2200487)（https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8...

Dec 14, 2022

IND Application of Biosyngen’s Cell Therapy (BRG01) for Naso

On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as “Biosyngen”) made an announcement on the approval granted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the company’s...